Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype

Immunohistochemistry can sub‐classify diffuse large B‐cell lymphoma (DLBCL) into germinal centre B‐cell like (GCB) and non‐GCB subtypes. The latter consists predominately of the activated B‐cell like subgroup in which nuclear factor kappa‐B activation is its characteristic. Expression of cellular ca...

Full description

Saved in:
Bibliographic Details
Published in:Hematological oncology 2012-03, Vol.30 (1), p.8-12
Main Authors: Harris, Jemima, Ibrahim, Hazem, Amen, Furrat, Karadimitris, Anastasios, Naresh, Kikkeri N, Macdonald, Donald H
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
apoptosis
Apoptosis - physiology
CASP8 and FADD-Like Apoptosis Regulating Protein - biosynthesis
CASP8 and FADD-Like Apoptosis Regulating Protein - genetics
cFLIP
Female
Humans
Immunohistochemistry
Immunophenotyping
lymphoma
Lymphoma, Large B-Cell, Diffuse - classification
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - metabolism
Lymphoma, Large B-Cell, Diffuse - pathology
Male
Middle Aged
Prognosis
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunohistochemistry can sub‐classify diffuse large B‐cell lymphoma (DLBCL) into germinal centre B‐cell like (GCB) and non‐GCB subtypes. The latter consists predominately of the activated B‐cell like subgroup in which nuclear factor kappa‐B activation is its characteristic. Expression of cellular caspase 8 (FLICE)‐like inhibitory protein (cFLIP), a caspase 8 homologue, is regulated by nuclear factor kappa‐B signalling, and it is the main inhibitor of Fas ligand activated apoptosis. To determine if cFLIP expression was confined to non‐GCB subtype, we studied 66 cases of DLBCL. cFLIP expression showed no significant correlation to DLBCL subtypes (GCB or non‐GCB) but was associated with a worse clinical outcome. For cFLIP positive and negative patients, the five‐year event free survival was 20 and 31%, respectively (p = 0.049), and the five‐year overall survival was 20 and 57%, respectively (p = 0.041). Copyright © 2011 John Wiley & Sons, Ltd.
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.996